



SRL 6067
PATENT

6067/1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Gary S. Jacob et al.

Serial No. 09/023401

Filed February 12, 1998

For USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL
COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS
VIRUS INFECTIONS

#3
HKO
8.27.98

August 14, 1998

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

RECEIVED

LETTER TO THE PATENT AND TRADEMARK OFFICE AUG 24 1998

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP
609, and in compliance with the duty of disclosure set forth in
37 C.F.R. 1.56, applicants submit copies of the references
listed on the attached PTO Form 1449 (modified) for
consideration by the Patent and Trademark Office in the above-
entitled application and to be made of record herein.

Respectfully submitted,

Charles E. Cohen

Charles E. Cohen, Reg. No. 34,565
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

CERTIFICATE OF MAILING

I certify that this Letter to the Patent and
Trademark Office and attached PTO Form 1449 is being deposited
with the United States Postal Service as first class mail,
postage prepaid, in an envelope addressed to: Assistant
Commissioner for Patents, Washington, D.C. 20231 on this 14th
day of August 1998.

Laura E. Polk

Laura E. Polk

CEC/lep
*Attachments

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
SRL 6067SERIAL NO.
09/023401

RECEIVED

LIST OF PRIOR ART CITED BY APPLICANT

AUG 24 1998

MATERIAL (Use several sheets if necessary)

MATR
SERVICE CENTER

AUG 18 1998

PATENT & TRADEMARK OFFICE

APPLICANT
Jacob, et al.FILING DATE
February 12, 1998

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
1	4,639,436	01/27/87	Junge, et al.	514	24	08/23/78

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
2	WO95/19172	07/20/95	PCT				
3	WO93/18763	09/30/93	PCT				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

4	/	Block, et al., "Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking", Nature Medicine, May 1998, Vol. 4, No. 5, pp. 610-614
5	/	Korba, et al., "Effectiveness of Combination Therapies with 3TC, Famciclovir, and Alpha interferon against Woodchuck Hepatitis Virus Replication in Chronically-infected Woodchucks: Model for Potential Anti-HBV Treatments", Antiviral Research, April 1997, Vol. 34(2), Abstract No. 37, p. A52
6		Lu, et al., "Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited", Proc. Natl. Acad. Sci., 1997, Vol. 94, pp. 2380-2385
7		Hoofnagle, et al., "The treatment of chronic viral hepatitis", Drug Therapy, 1997, Vol. 336, No. 5, pp. 347-356
8		Korba, et al., "Antiviral effectiveness of 3TC, famciclovir, and interferon against chronic WHV replication-Potential for combination therapy", Abstracts of papers presented at the meeting on Molecular Biology of hepatitis B viruses, 1996, p. 201
9		Rosina, et al., "Recent developments in the treatment of hepatitis D infection", Exp. Opin. Invest. Drugs, 1996, 5(2), pp. 197-205
10		John Rhodes, "Therapeutic potential of Schiff base-forming drugs", Exp. Opin. Invest. Drugs, 1996, 5(3), pp. 257-268
11	/	Locarnini, et al., "Hepatitis B: New approaches for antiviral chemotherapy", Antiviral Chemistry & Chemotherapy, 1996, 7(2), pp. 53-64
12		Blum, et al., "Antiviral therapy of hepatitis B virus infection: Blocking viral gene expression", Advanced Drug Delivery Reviews, 1995, Vol. 17, pp. 321-331
13		Coates, et al., "Developments in viral hepatitis during 1994", Exp. Opin. Ther. Patents, 1995, 5(8), pp. 747-756
14		Dienstag, et al., "A preliminary trial of lamivudine for chronic hepatitis B infection", New England Journal of Medicine, 1995, Vol. 333, No. 25, pp. 1657-1661
15		G.M. Dusheiko, "Treatment and prevention of chronic viral hepatitis", Pharmac. Ther., 1995, Vol. 65, pp. 47-73

16		Gish, et al., "Recent developments in the treatment of chronic hepatitis B virus infection", Exp. Opin. Invest. Drugs, 1995, 4(2), pp. 95-115
17	/	Brent E. Korba, "In vitro evaluation of combination therapies against hepatitis B virus replication", Antiviral Research, 1995, Vol. 29, pp. 49-51
18		Mutchnick, et al, "Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents", Antiviral Research, 1994, Vol. 24, pp. 245-257
19		Tan, et al., "Introduction of oxygen into the alkyl chain of N-decyl-dNM decreases lipophilicity and results in increased retention of glucose residues on N-linked oligosaccharides", Glycobiology, 1994, Vol. 4, No. 2, pp. 141-149
20		E.H.H. Wiltink, "Future prospects in antiviral therapy", Pharmaceutisch Weekblad-Scientific edition, 1992, 14(4A), pp. 268-274
21		Doong, et al., "Inhibition of the replication of hepatitis B virus in vitro by 2', 3'-dideoxy-3'-thiacytidine and related analogues", Proceedings of the National Academy of Sciences of the United States of America, 1991, 88(19), pp. 8495-8499 (abstract only)
22	/	Repp, et al., "The Effects of Processing Inhibitors of N-Linked Oligosaccharides on the Intracellular Migration of Glycoprotein E2 of Mouse Hepatitis Virus and the Maturation of Coronavirus Particles", The Journal of Biological Chemistry, 1985, Vol. 260, No. 29, pp. 15873-15879

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

